Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Mangoceuticals (MGRX) Invested Capital (2023 - 2025)

Mangoceuticals' Invested Capital history spans 3 years, with the latest figure at $15.7 million for Q3 2025.

  • For Q3 2025, Invested Capital rose 13.74% year-over-year to $15.7 million; the TTM value through Sep 2025 reached $15.7 million, up 13.74%, while the annual FY2024 figure was $13.9 million, 1700.07% up from the prior year.
  • Invested Capital for Q3 2025 was $15.7 million at Mangoceuticals, down from $19.2 million in the prior quarter.
  • Across five years, Invested Capital topped out at $20.3 million in Q1 2025 and bottomed at -$958468.0 in Q1 2024.
  • The 3-year median for Invested Capital is $13.8 million (2024), against an average of $9.5 million.
  • The largest annual shift saw Invested Capital plummeted 125.1% in 2024 before it surged 2212.82% in 2025.
  • A 3-year view of Invested Capital shows it stood at $774754.0 in 2023, then soared by 1700.07% to $13.9 million in 2024, then increased by 12.79% to $15.7 million in 2025.
  • Per Business Quant, the three most recent readings for MGRX's Invested Capital are $15.7 million (Q3 2025), $19.2 million (Q2 2025), and $20.3 million (Q1 2025).